

AdisInsight Newsletter | September

adisinsight.springer.com[Request a quote](#)[Request a trial](#)[Request a demo](#)

1. Shanghai Henlius Biotech collaborates with HanchorBio to advance the development of innovative immunotherapies

HanchorBio entered into a strategic agreement for collaboration with Shanghai Henlius Biotech (subsidiary of Shanghai Fosun Pharmaceutical) to combine HanchorBio's protein engineering expertise and proprietary Fc-based designer biologics (FBDB™) technology platform with Henlius' integrated product development and commercialization capabilities. The collaboration aims to expand the application of each company's platform by developing novel cancer immunotherapies, including those tumors resistant to anti-PD-1/L1 immunotherapies, to accelerate their respective pipeline of innovative immunotherapy medicines.

2. XNK Therapeutics collaborates with Karolinska University Hospital for the development of next generation NK cell-based cancer immunotherapy in AML

XNK Therapeutics entered into a R&D agreement with Karolinska University Hospital to evaluate the suitability of the company's autologous natural killer (NK) cell therapy candidate XNK02 for treatment of acute myeloid leukemia (AML). The company is using its proprietary technology platform for developing autologous natural killer cell-based therapies including a selective expansion and activation of NK cells from the peripheral blood of patients with cancer.

3. Fresenius Kabi partners with Lupagen to bring cell and gene therapies to the bedside

Fresenius Kabi and Lupagen entered into strategic development and supply agreement to bring cell and gene therapies to the bedside. Under the terms of the agreement, Fresenius Kabi will provide their expertise in apheresis collection and automated cell processing equipment to advance Lupagen's Extracorporeal Cell and Gene Therapy Delivery System, which focuses on simplifying and reducing costs for cell and gene therapy through a bedside procedure. The agreement covers both technology development and supply agreements.

4. Imunon collaborates under a CRADA with the National Institute of Allergy and Infectious Diseases to evaluate DNA-based Lassa virus vaccine candidates

Imunon entered into a Cooperative Research and Development Agreement (CRADA) with the National Institute of Allergy and Infectious Diseases (NIAID) to evaluate the immunogenicity and efficacy of two Imunon DNA-based Lassa virus vaccine candidates. In accordance with the three-year arrangement, the NIAID will evaluate the efficacy of PlaCCine DNA constructs against Lassa virus in guinea pig and non-human primate disease models, including both prime and prime-boost vaccine strategies.

5. Sinorda Biomedicine collaborates with Sanyou Biopharmaceuticals to advance their bispecific antibody drug project

Sanyou Biopharmaceuticals and Sinorda Biomedicine entered into a R&D agreement to advance Sinorda's bispecific antibody drug project. Under the terms of the agreement, Sanyou's core technology platform for integrated R&D and preclinical development of innovative biological drugs along with a "super-trillion innovative biologics discovery platform" will be leveraged to advance the R&D of the product pipeline through cooperative efforts.

6. Chiesi Global Rare Diseases partners with Aliada Therapeutics to advance blood-Brain Barrier-crossing platform technology in Lysosomal Storage Disorders

Chiesi Global Rare Diseases announced a co-development agreement with Aliada Therapeutics to address challenging disease areas with high unmet need. The research collaboration will focus on multiple enzyme cargoes modified with Aliada's Modular Delivery (MODEL) platform, which harnesses endogenous brain endothelial cell transport mechanisms to efficiently move large molecule therapeutics across the blood brain barrier (BBB) for lysosomal storage disorders (LSD).

7. CytoMed collaborates with Hangzhou CNK Therapeutics to enhance the persistence of CAR- $\gamma\delta$ T cells

CytoMed Therapeutics entered into research and development agreement with Hangzhou CNK Therapeutics for the development of allogeneic CAR- T cell therapy. Under this agreement, CytoMed will utilize CNK's PiggyBac technology to permanently graft the Chimeric Antigen Receptor (CAR) gene into its gamma delta T cells via a non-viral gene editing method.

8. HitGen partners with Nested Therapeutics based on its DEL technology

HitGen entered into a research service agreement with Nested Therapeutics to develop small molecules. HitGen will utilise its DNA-encoded library (DEL) technology platform, centered around the design, synthesis and screening of DELs, to identify hits against targets of interest to Nested.

9. Evox Therapeutics partners with Icahn School of Medicine at Mount Sinai Sinai to advance AAV gene therapy for heart disease

Evox Therapeutics and Icahn School of Medicine at Mount Sinai (Icahn Mount Sinai) entered into a research collaboration and option agreement to advance next generation exosome-delivered AAV gene therapy for the treatment of heart disease. The collaboration will work on developing exosome-encapsulated AAV (exoAAV) vectors as a novel gene delivery technology aimed at improving treatments for heart disease. Further details of the agreement are undisclosed.

10. Emergent BioSolutions receives a 10-year BARDA contract for advanced Ebola treatment

Emergent BioSolutions announced that it was awarded a 10-year contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS), valued at up to a maximum of \$US 704 million, for advanced development, manufacturing scale-up, and procurement of ansumivab (mAb114), an experimental Ebola treatment. The 10-year contract consists of a base period of performance with two option periods for advanced development valued at approximately \$US 121 million, and option periods for procurement of ansumivab treatment over five years valued at up to \$US 583 million.

About AdisInsight

AdisInsight is a comprehensive database based on scientific data containing information on drugs in development, clinical trials, drug safety, company deals and patents, dedicated to helping clients accurately, comprehensively, and cost-effectively monitor the growing amount of information available on drugs in development.

For more information and/or to request a free demo with our team, click on the button below to complete and submit your request.

[Request a demo](#)